SU-GG-T-135: Comparison of Treatment Planning Systems in Elekta Volumetric Modulated Arc Therapy (Elekta VMAT) - Prostate Cancer Study

2010 ◽  
Vol 37 (6Part17) ◽  
pp. 3215-3215
Author(s):  
A Haga ◽  
S Kida ◽  
Y Okano ◽  
S Itoh ◽  
T Matsuura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Cancer Study ◽  
Treatment Planning Systems ◽  
Arc Therapy ◽  
Prostate Cancer Study

scholarly journals Comparison between two treatment planning systems for volumetric modulated arc therapy optimization for prostate cancer

2014 ◽  
Vol 30 (1) ◽  
pp. 2-9 ◽  
Author(s):  
Caroline Lafond ◽  
Frédéric Gassa ◽  
Christophe Odin ◽  
Gaël Dréan ◽  
Justine Even ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Treatment Planning Systems ◽  
Arc Therapy

scholarly journals Delivery Parameter Variations and Early Clinical Outcomes of Volumetric Modulated Arc Therapy for 31 Prostate Cancer Patients: An Intercomparison of Three Treatment Planning Systems

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Shinichi Tsutsumi ◽  
Masako N. Hosono ◽  
Daisaku Tatsumi ◽  
Yoshitaka Miki ◽  
Yutaka Masuoka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Volumetric Modulated Arc Therapy ◽  
Planning Systems ◽  
Treatment Planning Systems ◽  
Dose Volume ◽  
Parameter Variations ◽  
Arc Therapy ◽  
The Mean ◽  
Mean Dose Rate ◽  
Early Clinical Outcomes

We created volumetric modulated arc therapy (VMAT) plans for 31 prostate cancer patients using one of three treatment planning systems (TPSs)—ERGO++, Monaco, or Pinnacle—and then treated those patients. A dose of 74 Gy was prescribed to the planning target volume (PTV). The rectum, bladder, and femur were chosen as organs at risk (OARs) with specified dose-volume constraints. Dose volume histograms (DVHs), the mean dose rate, the beam-on time, and early treatment outcomes were evaluated and compared. The DVHs calculated for the three TPSs were comparable. The mean dose rates and beam-on times for Ergo++, Monaco, and SmartArc were, respectively, 174.3 ± 17.7, 149.7 ± 8.4, and 185.8 ± 15.6 MU/min and 132.7 ± 8.4, 217.6 ± 13.1, and 127.5 ± 27.1 sec. During a follow-up period of 486.2 ± 289.9 days, local recurrence was not observed, but distant metastasis was observed in a single patient. Adverse events of grade 3 to grade 4 were not observed. The mean dose rate for Monaco was significantly lower than that for ERGO++ and SmartArc (P<0.0001), and the beam-on time for Monaco was significantly longer than that for ERGO++ and SmartArc (P<0.0001). Each TPS was successfully used for prostate VMAT planning without significant differences in early clinical outcomes despite significant TPS-specific delivery parameter variations.

scholarly journals Influence of cleaned-up commercial knowledge-based treatment planning on volumetric-modulated arc therapy of prostate cancer

2020 ◽  
Vol 45 (2) ◽  
pp. 71 ◽  
Author(s):  
Hajime Monzen ◽  
Mikoto Tamura ◽  
Kenji Matsumoto ◽  
Kazuki Kubo ◽  
Yoshihiro Ueda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Planning ◽  
Volumetric Modulated Arc Therapy ◽  
Knowledge Based ◽  
Arc Therapy
Sign in / Sign up

Export Citation Format

Share Document